Esperion Therapeutics, Inc. (0IIM.L)
USD 0.88
(-11.04%)
USD 0.88
(-11.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -150.1 Million USD | 12.13% |
| 2022 | -176.34 Million USD | 20.61% |
| 2021 | -222.14 Million USD | -84.28% |
| 2020 | -120.33 Million USD | -35.75% |
| 2019 | -88.72 Million USD | 56.48% |
| 2018 | -204.32 Million USD | -22.66% |
| 2017 | -166.53 Million USD | -123.57% |
| 2016 | -74.35 Million USD | -51.43% |
| 2015 | -49.02 Million USD | -36.45% |
| 2014 | -36.06 Million USD | -60.51% |
| 2013 | -22.68 Million USD | -121.66% |
| 2012 | -10.11 Million USD | -0.86% |
| 2011 | -10.06 Million USD | 0.0% |
| 2002 | -27.21 Million USD | -1.53% |
| 2001 | -26.8 Million USD | -23.39% |
| 2000 | -25.52 Million USD | -85.9% |
| 1999 | -11.68 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.58 Million USD | -164.22% |
| 2024 Q1 | 72.26 Million USD | 281.79% |
| 2023 FY | - USD | 12.13% |
| 2023 Q4 | -42.36 Million USD | -53.86% |
| 2023 Q2 | -37.05 Million USD | 21.71% |
| 2023 Q1 | -47.33 Million USD | -15.0% |
| 2023 Q3 | -27.53 Million USD | 25.7% |
| 2022 Q4 | -41.15 Million USD | -0.73% |
| 2022 Q3 | -40.85 Million USD | 21.51% |
| 2022 Q2 | -52.05 Million USD | -22.44% |
| 2022 Q1 | -42.51 Million USD | 17.75% |
| 2022 FY | - USD | 20.61% |
| 2021 Q4 | -51.68 Million USD | 7.0% |
| 2021 Q3 | -55.57 Million USD | -71.69% |
| 2021 FY | - USD | -84.28% |
| 2021 Q1 | -82.65 Million USD | 13.49% |
| 2021 Q2 | -32.37 Million USD | 60.84% |
| 2020 Q2 | 129.36 Million USD | 274.89% |
| 2020 FY | - USD | -35.75% |
| 2020 Q1 | -73.97 Million USD | -27.93% |
| 2020 Q3 | -80.34 Million USD | -162.11% |
| 2020 Q4 | -95.54 Million USD | -18.92% |
| 2019 Q4 | -57.82 Million USD | 10.06% |
| 2019 FY | - USD | 56.48% |
| 2019 Q1 | 87 Million USD | 243.45% |
| 2019 Q2 | -55.24 Million USD | -163.5% |
| 2019 Q3 | -64.28 Million USD | -16.37% |
| 2018 Q3 | -50.49 Million USD | -8.79% |
| 2018 Q4 | -60.64 Million USD | -20.11% |
| 2018 FY | - USD | -22.66% |
| 2018 Q1 | -46.83 Million USD | -23.7% |
| 2018 Q2 | -46.41 Million USD | 0.89% |
| 2017 Q2 | -43.21 Million USD | -6.96% |
| 2017 Q1 | -40.4 Million USD | -39.92% |
| 2017 Q3 | -45.11 Million USD | -4.39% |
| 2017 FY | - USD | -123.57% |
| 2017 Q4 | -37.85 Million USD | 16.08% |
| 2016 FY | - USD | -51.43% |
| 2016 Q2 | -13.87 Million USD | 3.73% |
| 2016 Q1 | -14.41 Million USD | -10.85% |
| 2016 Q3 | -17.25 Million USD | -24.34% |
| 2016 Q4 | -28.87 Million USD | -67.41% |
| 2015 Q3 | -12.61 Million USD | -3.38% |
| 2015 Q4 | -13 Million USD | -3.04% |
| 2015 Q1 | -11.27 Million USD | -20.92% |
| 2015 Q2 | -12.2 Million USD | -8.26% |
| 2015 FY | - USD | -36.45% |
| 2014 Q3 | -9.62 Million USD | -4.61% |
| 2014 Q4 | -9.32 Million USD | 3.09% |
| 2014 Q2 | -9.19 Million USD | -16.97% |
| 2014 Q1 | -7.86 Million USD | 18.77% |
| 2014 FY | - USD | -60.51% |
| 2013 Q2 | -4.25 Million USD | -27.4% |
| 2013 Q1 | -3.33 Million USD | -50.74% |
| 2013 Q4 | -9.67 Million USD | -85.13% |
| 2013 Q3 | -5.22 Million USD | -22.98% |
| 2013 FY | - USD | -121.66% |
| 2012 FY | - USD | -0.86% |
| 2012 Q3 | -2.95 Million USD | -4.49% |
| 2012 Q2 | -2.82 Million USD | -31.43% |
| 2012 Q1 | -2.15 Million USD | 0.0% |
| 2012 Q4 | -2.21 Million USD | 25.09% |
| 2011 FY | - USD | 0.0% |
| 2003 Q3 | -6.22 Million USD | 19.2% |
| 2003 Q2 | -7.83 Million USD | -7.44% |
| 2003 Q1 | -7.08 Million USD | -18.17% |
| 2002 FY | - USD | -1.53% |
| 2002 Q4 | -6.19 Million USD | 18.93% |
| 2002 Q3 | -7.23 Million USD | -6.71% |
| 2002 Q2 | -7.3 Million USD | 7.46% |
| 2002 Q1 | -7.35 Million USD | -15.95% |
| 2001 Q2 | -7.66 Million USD | 4.43% |
| 2001 Q1 | -8.02 Million USD | -101.25% |
| 2001 FY | - USD | -23.39% |
| 2001 Q4 | -6.26 Million USD | -4.1% |
| 2001 Q3 | -6.29 Million USD | 20.78% |
| 2000 Q2 | -7.56 Million USD | -34.33% |
| 2000 Q1 | -5.62 Million USD | 0.0% |
| 2000 Q4 | -5.04 Million USD | 7.9% |
| 2000 FY | - USD | -85.9% |
| 2000 Q3 | -7.75 Million USD | 42.76% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Imunon, Inc. | -20.78 Million USD | -622.289% |
| Homology Medicines, Inc. | -47.75 Million USD | -214.323% |
| uniQure N.V. | -253.1 Million USD | 40.692% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -196.82% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -70.606% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 56.549% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -63.021% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 43.568% |
| bluebird bio, Inc. | -167.16 Million USD | 10.202% |
| Blueprint Medicines Corporation | -474.61 Million USD | 68.372% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -27.589% |
| Adicet Bio, Inc. | -136.53 Million USD | -9.941% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1652.948% |
| Editas Medicine, Inc. | -163.11 Million USD | 7.975% |
| Geron Corporation | -174.78 Million USD | 14.117% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -44.624% |
| Illumina, Inc. | -608 Million USD | 75.311% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 66.569% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 104.61% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 112.895% |
| Myriad Genetics, Inc. | -67.8 Million USD | -121.398% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 136.075% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 65.822% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 252.763% |
| Verastem, Inc. | -83.16 Million USD | -80.492% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 98.669% |
| Waters Corporation | 1.02 Billion USD | 114.684% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 103.26% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 101.39% |
| Biogen Inc. | 2.37 Billion USD | 106.315% |
| Nektar Therapeutics | -243.1 Million USD | 38.254% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -48.877% |
| Perrigo Company plc | 646.2 Million USD | 123.229% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -302.618% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -237.802% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 148.378% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -71.695% |
| Evolus, Inc. | -41.81 Million USD | -259.024% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 103.225% |
| FibroGen, Inc. | -261.4 Million USD | 42.576% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 108.951% |
| OPKO Health, Inc. | -65.51 Million USD | -129.117% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 34.198% |
| Exelixis, Inc. | 196.6 Million USD | 176.351% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -169.223% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 70.353% |
| Zoetis Inc. | 3.68 Billion USD | 104.073% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 33.283% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -316.019% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 34.738% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 238.573% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 133.214% |
| Insmed Incorporated | -654.73 Million USD | 77.074% |
| TG Therapeutics, Inc. | 26.1 Million USD | 675.126% |
| Incyte Corporation | 919.42 Million USD | 116.326% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 70.293% |